BAZ2B

Across TCGA pan-cancer cohorts, BAZ2B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated BAZ2B data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BAZ2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BAZ2B expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

LUAD, OV, and GBM are the cancer types where BAZ2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.318	0.774	.004	9	view →
OV	DFS	Median	All	0.803	0.978	.043	8	view →
GBM	OS	Median	All	0.490	0.270	.011	5	view →
PDAC	DFS	Quartile	All	0.666	0.930	.025	4	view →
UCEC	DFS	Quartile	III,IV	1.000	0.460	.040	4	view →
HNSC	OS	Quartile	All	0.824	0.623	.025	2	view →
LSCC	OS	Median	III,IV	0.831	0.492	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

BAZ2B–LUAD (OS)

Open the LUAD breakdown →